
USD
+$0.00
(+0.00%
)At Close (As of Dec 11, 2025)
$6.99B
Market Cap
-
P/E Ratio
-3.1
EPS
$122.20
52 Week High
$45.91
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$114M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $1.6M |
| Capital Expenditures | $0 |
| Change In Receivables | - |
| Change In Inventory | -$10M |
| Profit Loss | - |
| Cashflow From Investment | -$48M |
| Cashflow From Financing | $191M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | $4M |
| Dividend Payout Common Stock | $4M |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$261M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Rhythm Pharmaceuticals, Inc. is a Boston-based biopharmaceutical innovator focused on developing groundbreaking therapies for rare genetic obesity disorders. The company's flagship product, Imcivree (setmelanotide), targets the underlying biological mechanisms of severe obesity associated with specific genetic conditions, providing critical treatment options for an underserved patient demographic. Leveraging its expertise in melanocortin system research, Rhythm is poised to expand its pipeline, further enhancing patient outcomes and quality of life, and reinforcing its leadership position at the intersection of genetic medicine and metabolic health.